Published in Ann Rheum Dis on October 01, 1986
Epidemiology of scleroderma. Ann Rheum Dis (1991) 1.13
Autoimmune diseases and autoantibodies in the first degree relatives of patients with systemic sclerosis. J Autoimmun (2010) 1.01
Antikinetochore and antitopoisomerase I antibodies in systemic scleroderma: comparative study using immunoblotted recombinant antigens, immunofluorescence, and double immunodiffusion. Arch Dermatol Res (1990) 0.85
Antinuclear antibodies in patients with scleroderma (systemic sclerosis) and in their blood relatives and spouses. Ann Rheum Dis (1993) 0.82
Major histocompatibility complex class II genes and systemic sclerosis. Ann Rheum Dis (1991) 0.82
Is occupational exposure to solvents associated with an increased risk for developing systemic scleroderma? J Occup Med Toxicol (2006) 0.78
An immunogenetic study of familial scleroderma. Ann Rheum Dis (1994) 0.75
Genetic polymorphism in human glycine-rich beta-glycoprotein. J Exp Med (1972) 5.61
Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum (1980) 3.87
Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem (1979) 2.99
Serum antinuclear antibodies in progressive systemic sclerosis (scleroderma). Arthritis Rheum (1968) 2.30
Prevalence of disease among vinyl chloride and polyvinyl chloride workers. Ann N Y Acad Sci (1975) 2.04
Anticentromere and anticentriole antibodies in the scleroderma spectrum. Arch Dermatol (1983) 1.95
Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis (1983) 1.55
Toxic-allergic syndrome caused by ingestion of rapeseed oil denatured with aniline. Lancet (1981) 1.45
Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol (1981) 1.34
Antibodies to a nuclear/nucleolar antigen in patients with polymyositis overlap syndromes. J Clin Immunol (1984) 1.30
Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum (1981) 1.27
Anti-nucleic acid antibodies in systemic lupus erythematosus patients and their families. Incidence and correlation with lymphocytotoxic antibodies. J Clin Invest (1975) 1.19
Association of HLA antigen a9 with progressive systemic sclerosis (scleroderma). Tissue Antigens (1978) 1.07
Family studies of complement C4 and HLA in man. Hum Genet (1981) 1.04
HLA antigens, autoantibodies and clinical subsets in scleroderma. Br J Rheumatol (1984) 1.03
Antinuclear antibodies in the relatives of patients with systemic sclerosis. Br J Dermatol (1985) 0.98
Systemic scleroderma in mother and daughter. Arch Dermatol (1977) 0.97
The immunopathology of progressive systemic sclerosis (PSS). Semin Arthritis Rheum (1982) 0.94
Comparative studies of antilymphocyte, antipolynucleotide, and antiviral antibodies among families of patients with systemic lupus erythematosus. Arthritis Rheum (1978) 0.92
Three siblings with scleroderma (systemic sclerosis) and two with Raynaud's phenomenon from a single kindred. Arthritis Rheum (1981) 0.92
Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma). J Clin Immunol (1982) 0.90
Familial lupus. Family studies of HLA and serologic findings. Arthritis Rheum (1978) 0.88
"Familial" scleroderma. Arch Dermatol (1969) 0.87
Familial progressive systemic scleroderma. Arch Dermatol (1975) 0.86
Progressive systemic sclerosis in a family: case report of a mother and son and review of the literature. Arthritis Rheum (1977) 0.86
Familial scleroderma. Ann Phys Med (1965) 0.82
Familial progressive systemic sclerosis (scleroderma): immunological analysis of two patients and six siblings from a single kindred. Clin Exp Immunol (1982) 0.81
Conjugal progressive systemic sclerosis (scleroderma): report of the disease in husband and wife. Arthritis Rheum (1984) 0.80
Familial CRST syndrome with sicca complex. J Rheumatol (1977) 0.80
Familial scleroderma. Br J Dermatol (1974) 0.80
The CREST syndrome variant of scleroderma in a mother-daughter pair. J Rheumatol (1978) 0.78
Familial localized scleroderma (morphoea) Arch Dermatol (1977) 0.78
Scleroderma, immunological and genetic disease in three families. Dermatologica (1969) 0.77
SCLERODERMA: PERIODONTAL MEMBRANE MANIFESTATIONS IN TWO BROTHERS. Periodontics (1965) 0.77
Scleroderma with intestinal involvement: fatal in two of a kindred. J Rheumatol (1977) 0.77
Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens (1995) 6.33
The hypermobility syndrome. Musculoskeletal complaints associated with generalized joint hypermobility. Ann Rheum Dis (1967) 4.99
Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet (1996) 4.33
Controlled trial of mobilisation and manipulation for patients with low back pain in general practice. Br Med J (1978) 3.53
Valvular mechanisms in juxta-articular cysts. Ann Rheum Dis (1970) 3.47
CTGF and SMADs, maintenance of scleroderma phenotype is independent of SMAD signaling. J Biol Chem (2001) 3.28
Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up. Br Med J (1973) 3.27
Acute joint rupture. Ann Phys Med (1969) 3.20
Estimating the prevalence of low back pain in the general population. Evidence from the South Manchester Back Pain Survey. Spine (Phila Pa 1976) (1995) 3.18
Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) (2004) 3.12
Evaluation of polymerase chain reaction for diagnosis of pneumococcal pneumonia. J Clin Microbiol (1993) 3.04
Intra-articular pressure in rheumatoid arthritis of the knee. I. Pressure changes during passive joint distension. Ann Rheum Dis (1970) 2.96
Family study of the major histocompatibility complex in patients with systemic lupus erythematosus: importance of null alleles of C4A and C4B in determining disease susceptibility. Br Med J (Clin Res Ed) (1983) 2.86
Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis (2003) 2.85
A disease severity scale for systemic sclerosis: development and testing. J Rheumatol (1999) 2.85
Naproxen. A new non-hormonal anti-inflammatory agent. Studies in rheumatoid arthritis. Ann Rheum Dis (1974) 2.77
Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction? J Rheumatol (1994) 2.76
The specificity of fetal IgM: antibody or anti-antibody? Ann N Y Acad Sci (1975) 2.65
Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility. Lancet (1980) 2.63
Predicting who develops chronic low back pain in primary care: a prospective study. BMJ (1999) 2.62
A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl (1987) 2.62
HLA-DR4 subtype frequencies in rheumatoid arthritis indicate that DRB1 is the major susceptibility locus within the HLA class II region. Proc Natl Acad Sci U S A (1989) 2.60
Heberden Oration, 1977. Chronic arthritis in childhood. Ann Rheum Dis (1978) 2.55
Nerve ingrowth into diseased intervertebral disc in chronic back pain. Lancet (1997) 2.52
Fluoridation and the rheumatic diseases. A comparison of rheumatism in Watford and Leigh. Ann Rheum Dis (1966) 2.52
HLA-DR antigens and toxic reaction to sodium aurothiomalate and D-penicillamine in patients with rheumatoid arthritis. N Engl J Med (1980) 2.52
Antibody-dependent cell-mediated cytotoxicity to target cells infected with type 1 and type 2 herpes simplex virus. J Immunol (1976) 2.49
European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis (2001) 2.49
Spondylo-epiphysial dysplasia tarda with progressive arthropathy. A "new" disorder of autosomal recessive inheritance. J Bone Joint Surg Br (1982) 2.47
A limited role for manipulation. Br Med J (Clin Res Ed) (1986) 2.46
HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A (1999) 2.45
The promise of integrated representative surveys about sexually transmitted diseases and behavior. Sex Transm Dis (1997) 2.44
Raised IgG antiglobulin factors in Still's disease. Ann Rheum Dis (1969) 2.39
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Development and validation of a questionnaire to assess disabling foot pain. Pain (2000) 2.34
Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome. Infect Immun (1993) 2.32
Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. Arthritis Rheum (1994) 2.30
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis (2006) 2.28
Intra-articular pressure and rheumatoid geodes (bone 'cysts'). Ann Rheum Dis (1970) 2.28
Serological findings in patients with "ANA-negative" systemic lupus erythematosus. Medicine (Baltimore) (1981) 2.27
Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med (1982) 2.26
Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block. N Engl J Med (1983) 2.24
Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. Lancet (1981) 2.23
Influence of previous pain experience on the episode incidence of low back pain: results from the South Manchester Back Pain Study. Pain (1996) 2.17
Evaluation of bias in diagnostic-test sensitivity and specificity estimates computed by discrepant analysis. J Clin Microbiol (1998) 2.14
Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM (2007) 2.14
Preliminary report: dramatic rise in renal allograft failure rate. Lancet (1990) 2.09
Role of superoxide dismutase and catalase as determinants of pathogenicity of Nocardia asteroides: importance in resistance to microbicidal activities of human polymorphonuclear neutrophils. Infect Immun (1985) 2.06
Septic arthritis. Ann Rheum Dis (1972) 2.06
Arthroscopy of the knee in rheumatic diseases. Ann Rheum Dis (1968) 2.06
Risk factors for neck pain: a longitudinal study in the general population. Pain (2001) 2.06
Evaluation of nucleic acid amplification tests as reference tests for Chlamydia trachomatis infections in asymptomatic men. J Clin Microbiol (2000) 2.02
Psychosocial factors in the workplace--do they predict new episodes of low back pain? Evidence from the South Manchester Back Pain Study. Spine (Phila Pa 1976) (1997) 2.01
Intra-articular pressure in rheumatoid arthritis of the knee. 3. Pressure changes during joint use. Ann Rheum Dis (1970) 2.00
Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol (1997) 2.00
Psychologic distress and low back pain. Evidence from a prospective study in the general population. Spine (Phila Pa 1976) (1995) 1.98
Controlled trial of mobilisation and manipulation for low back pain: hospital patients. Br Med J (1979) 1.95
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis. Rheumatology (Oxford) (2006) 1.94
Steroid cataract. Ann Rheum Dis (1966) 1.93
Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis (2000) 1.89
Failure of long surviving, passively enhanced kidney allografts to provoke T-dependent alloimmunity. I. Retransplantation of (AS X AUG)F1 kidneys into secondary AS recipients. J Exp Med (1979) 1.88
Anti-inflammatory lipocortin 1 production by peripheral blood leucocytes in response to hydrocortisone. Lancet (1990) 1.88
Childhood-onset scleroderma: is it different from adult-onset disease. Arthritis Rheum (1996) 1.85
The association of antinuclear antibodies with the chronic iridocyclitis of juvenile rheumatoid arthritis (Still's disease). Arthritis Rheum (1974) 1.84
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol (1988) 1.83
Comparison of arbitrarily primed polymerase chain reaction, ribotyping, and monoclonal antibody analysis for subtyping Legionella pneumophila serogroup 1. J Clin Microbiol (1993) 1.82
Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford) (2001) 1.82
Matrix metalloproteinases: the clue to intervertebral disc degeneration? Spine (Phila Pa 1976) (1998) 1.78
A pilot study of the prevalence of chlamydial infection in a national household survey. Sex Transm Dis (1998) 1.78
Corticosteroid-induced dwarfism in Still's disease treated with human growth hormone. Clinical and metabolic effects including hydroxyproline excretion in two cases. Ann Rheum Dis (1966) 1.78
Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet (1991) 1.76
Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet (1991) 1.76
Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem (2000) 1.74
Arthropathy of hands and feet in systemic lupus erythematosus. J Rheumatol (1990) 1.74
Oedema in rheumatoid arthritis: changes in the coefficient of capillary filtration. Br Med J (1971) 1.73
Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart (2005) 1.73
The influence of HLA class I alleles and heterozygosity on the outcome of human T cell lymphotropic virus type I infection. J Immunol (2000) 1.73
Psoriasis: aetiological aspects. Acta Derm Venereol (1965) 1.72
The grading of hallux valgus. The Manchester Scale. J Am Podiatr Med Assoc (2001) 1.70
D-Penicillamine induced toxicity in rheumatoid arthritis: the role of sulphoxidation status and HLA-DR3. J Rheumatol (1984) 1.69
Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes. Hybridoma (1984) 1.67
Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol (1998) 1.66
Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma. Rheumatology (Oxford) (2001) 1.66
Typing of Chlamydia trachomatis strains from urine samples by amplification and sequencing the major outer membrane protein gene (omp1). Sex Transm Infect (2001) 1.62
Serologic subsets in systemic lupus erythematosus: an examination of autoantibodies in relationship to clinical features of disease and HLA antigens. Arthritis Rheum (1980) 1.62
The source and role of RANTES in interstitial lung disease. Eur Respir J (1997) 1.62
Mechanisms underlying chronic back pain. BMJ (1994) 1.61
A functional polymorphism of the stromelysin gene (MMP-3) influences susceptibility to primary sclerosing cholangitis. Gastroenterology (2001) 1.60
Comprehensive, serologically equivalent DNA typing for HLA-B by PCR using sequence-specific primers (PCR-SSP). Tissue Antigens (1995) 1.59
Total hip replacement using the McKee-Farrar prosthesis. In rheumatoid arthritis, Still's disease, and ankylosing spondylitis. Ann Rheum Dis (1970) 1.58
Employment and physical work activities as predictors of future low back pain. Spine (Phila Pa 1976) (1997) 1.57
Production of beta 2-microglobulin by normal and malignant human cell lines and peripheral lymphocytes. Transplant Rev (1974) 1.57
Joint capsule collagen in osteoarthrosis. Ann Rheum Dis (1973) 1.57
Anti-Ro(SSA) positive rheumatoid arthritis (RA): a clinicoserological group of patients with high incidence of D-penicillamine side effects. Ann Rheum Dis (1985) 1.56